Most Recent
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
High-ranking bank officials, including the former CEOs of Citigroup and Deutsche Bank in Australia, are among the executives charged over a cartel involving a $2.5 billion ANZ institutional share placement.
The judge overseeing a competition case against Google by mobile advertising startup Unlockd has extended a temporary injunction to the search engine giant's US arm.
Hilton Worldwide -- which owns New York's iconic Waldorf Astoria hotel -- has won a bid to block an Australian serviced apartments provider from registering trade marks for the phrase "Waldorf Apartments".
The fate of class actions against Volkswagen in the sprawling Australian case over the car maker's diesel emissions cheating scandal will be the subject of a major court battle starting Wednesday.
Weight loss centre Jenny Craig has been ordered to pay a penalty for misleading television ads that promised people could lose up to 10 kilos for a $10 free.
Leading fundraising company Appco Australia Group is challenging a judge's decision to let a $85 million wage case move forward as a class action.
Luxury home builder Glenville has won an appeal of a ruling that shielded certain documents from production by legal professional privilege in a lawsuit against global packaging giant Amcor over liability for asbestos remediation at a former Amcor paper mill site in a Melbourne suburb.
The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.
Pharmaceutical giant Wyeth's has launched an "ambush" at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.